Cost and Clinical Implications of Utilizing Homologous Recombination Deficiency Status to Guide First-Line Maintenance Therapy Selection in Advanced Ovarian Cancer
With success comes overuse. A typical example of this is the widespread use of enzyme inhibitors, such as PARPi in ovarian cancer, for women who because of their genotype are unlikely to have any benefit.
The current cost in the US to treat 100 women with PARPi for ovarian cancer is just over $US 62 million for the 5-year treatment course. This imposes a strain on personal and community finances. If these patients are screened using a biomarker guide (BMG), the cost overall is reduced, (by 17.5%), despite the significant cost of performing BMG on 100 women.
Savings from treatment also include reduced clinical costs due to prolonged survival and better health. For costly treatment such as targeted enzyme inhibition, it is important to ensure it is only used when most cost-effective. This study shows that for each dollar spent on HRD testing, another twenty-six dollars of savings will result.
No comments:
Post a Comment